Compound H26, a derivative of corosolic acid, functions as Hypoglycemic agent 3. It exhibits lipid-lowering and significant blood glucose-reducing properties, making it a potential hypoglycemic drug. Hypoglycemic agent 3 targets MCCC1 to mitigate insulin resistance, and may be useful in researching type 2 diabetes.

Hypoglycemic agent 3 (Compound H26) shows no significant cytotoxicity in HepG2 cells at concentrations of 40-320 μM over 24 hours [1]. At 20-40 μM, it primarily inhibits insulin resistance by increasing MCCC1 in HepG2 cells [1]. At a concentration of 20 μM for 1 hour, it significantly suppresses the glucosamine-induced (18 mM; 18 h) increase in gluconeogenesis in these cells [1]. Additionally, at concentrations ranging from 2.5-20 μM for 1 hour, it activates the PI3K-AKT pathway and inhibits the NF-κB signaling pathway in HepG2 cells [1].